Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RNN...Yep, looking good. Hit 1.86 so far.
RNN..Now 1.63.:)
Hang Ten,
Thanks. I trade mostly by TA and of course do look at fundamentals in general. The chart has been in a terrible downtrend; however, the OBV to me is an indication that people are buying and holding. Apparently there are those that believe that something good will happen and are willing to wait it out. For those that aren't or have lost faith, there are many, many other stocks out there. Personally, if I don't care for a stock, I move on. I don't stay around bad-mouthing it. To me it's a waste of time and effort and I choose to spend my time more positively. I did some reading about the CEO and how many years he's been of the belief that this location with the permit will prove to be lucrative. Having traded penny stocks off and on for a number of years, I'm of the belief that if someone just wants to be in this for a relatively quick trade they should make money from the current price of .021. I do think they'll regain their OTCBB status and with that will come a move up. We'll see...:)
Lexi
I recently bought back into EEGC again. I'd traded it awhile back, but then just forgot about it. I decided to rebuy for these reasons:
First of all the OBV indicator told me that people are buying this stock. Notice how it has gone up. That is happening both on the daily and the weekly.
Next I noticed that it had been delisted from OTCBB, but was working on getting relisted.
In addition, I saw that they got the permit they've been wanting.
All in all, it seemed to me that this could be a multi-bagger for me. So....I bought.
Lexi
Thanks. I hardly ever play the below .25 stocks anymore; however, EEGC is one I'd played before and it came to my attention, so I got some. What interested me was this:
It got delisted from OTCBB and has been doing things to get back on.
They recently got a permit for use of land that they've been wanting for sometime and it's supposed to have a good amount of oil on it.
Looking at the chart, the OBV says to me both on the daily and the weekly that it has greatly improved.
My guess is that once this gets on OTCBB we'll see a nice move. Current price is .021.
Lexi
From: lexi2004 6/11/2010 10:25:15 AM
of 205255
AGEN moving up. @ .9089 Volume 257K
Antigenics Inc., a biotechnology company, develops and commercializes technologies to treat cancers and infectious diseases primarily based on immunological approaches. The company?s product includes Oncophage, a patient-specific therapeutic cancer vaccine tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma, as well as in Phase II clinical trial for the treatment of glioma. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is in Phase III third-party clinical trials for various diseases, including hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer?s disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program tested in a Phase I clinical trial for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic tested in a Phase I clinical trial for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics Inc. in February 2000. Antigenics Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
=====================
Antigenics Sees Encouraging Results; Good Long Term Pick
4 comments | by: VFC's Stock House May 26, 2010 | about: AGEN
It's been a long road for Antigenics (AGEN) since announcing that Russia had approved Oncophage for the treatment of kidney cancer in April of 2008, based on a subset of patients from a Phase III trial. Although the trial results were not thought to be encouraging enough to be brought before the US FDA, Antigenics applied for approval in Europe based on the same subset data that convinced Russia to approve, but were denied this time, sending the AGEN stock back to the sub-$1 level after having had an impressive run during 2009.
After trading at those levels for most of 2010, AGEN had a bit of a bounce back of late, hitting as high as just over $1.70, although no significant news had been released to spur such a spike in price.
Last week, however, the company announced encouraging results from a Phase I/II trial at the International Conference on Brain Tumor Research and Therapy, offering new life to Oncophage and drawing new attention to the stock. Any move towards approval is still a long way off, but Oncophage - awarded as the World Vaccine Congress "best therapeutic vaccine" in April, 2009 - could still have an impressive future, based on current developments and past events.
Oncophage is currently in various stages of development to treat a variety of cancer conditions and QS-21, Antigenics' vaccine adjuvant is being tested in numerous investigational vaccines and the company will receive some future royalty payments if any of those vaccines makes it to market.
It's also possible that Oncophage for kidney cancer is not a complete dud, as I believe that big pharma with big pockets could revive that indication in the event of either a buyout or partnership - a possibility that grows more probable with each passing day, in my opinion. I'm a fan of the future of cancer immunotherapy treatments, and it's still quite possible that Antigenics will play a large role in that future.
That said, AGEN is still a speculative stock and the current volatility should be used to flip a few trading shares, in my opinion, to protect against any future unexpected negative results.
I still like AGEN as a nice long term pick; any short to mid term stock gains would be the result of buyout / partnership talk or a revival of the kidney cancer treatment indication.
All just my opinion, each investor should do his or her own DD.
Disclosure: Long AGEN.
GDP.. Sorry I didn't reply earlier. Just read your post. I sold it for a profit, but can't remember where since I trade a lot of stocks.:)
Right now I'm trading some of the small bios. I got YMI at 1.3 and sold part at 1.72, then bought some back today in the low 1.50s. Also bought CVM. It just filled the gap at .65. Looking to get into AGEN when it fills the gap. I am holding CRXX, as I undertand it some news should be coming out next week.
This is from the Street.com's report on GNBT that I found in the research section of TDAmeritrade.
FINANCIAL ANALYSIS
GENEREX BIOTECHNOLOGY CORP's gross profit margin for the first quarter of its fiscal year 2010 has
significantly decreased when compared to the same period a year ago. Even though sales decreased, the net
income has increased. GENEREX BIOTECHNOLOGY CORP is extremely liquid. Currently, the Quick Ratio is 2.93
which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased
from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 71.77% from the same quarter
last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial
difficulties in the near future.
This is from the Street.com's report on GNBT that I found in the research section of TDAmeritrade.
FINANCIAL ANALYSIS
GENEREX BIOTECHNOLOGY CORP's gross profit margin for the first quarter of its fiscal year 2010 has
significantly decreased when compared to the same period a year ago. Even though sales decreased, the net
income has increased. GENEREX BIOTECHNOLOGY CORP is extremely liquid. Currently, the Quick Ratio is 2.93
which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased
from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 71.77% from the same quarter
last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial
difficulties in the near future.
GNBT...I'm not an attorney, but it seems to me I read somewhere if you bring suit and lose you have to pay court costs. If that's the case, it certainly seems to me to make this case with GNBT have even more credibility. In other words, they're not going to pursue something that's going to make them look bad in the end.
BTW, I added more shares to my already large amount of GNBT when the news came out GNBT was bringing suit.
Thank you. BTW, I added to my GNBT on the news that GNBT has filed a suit against the Street.com.
GDP...Thanks for the chart. It hit 16.27 as the HOD today and is 16.26 now in AHs.
GDP....In at 15.68. Stock has been going down, based a few days, and today passed the high of Friday. Currently @ 15.80.
Small float, good institutional ownership:
Float: 24.37M
% Held by Insiders1: 38.04%
% Held by Institutions1: 79.10%
Goodrich Petroleum Corporation, an independent oil and gas company, engages in the exploration, exploitation, development, and production of oil and natural gas properties in east Texas and northwest Louisiana. The company offers drilling activities and holds interests in various areas, including primarily North Minden, Beckville, Angelina River, South Henderson, Bethany Longstreet, Greenwood Waskom Metcalf, Longwood, and Caddo Pine Island. As of December 31, 2009, it had estimated proved reserves of approximately 415.3 billion cubic feet of natural gas and 0.9 million barrels of oil and condensate. It owned working interests in 466 active oil and gas wells located in 24 fields in 6 states. Goodrich Petroleum Corporation was founded in 1970 and is based in Houston, Texas.
GDP....In at 15.68. Stock has been going down, based a few days, and today passed the high of Friday. Currently @ 15.80.
Small float, good institutional ownership:
Float: 24.37M
% Held by Insiders1: 38.04%
% Held by Institutions1: 79.10%
Goodrich Petroleum Corporation, an independent oil and gas company, engages in the exploration, exploitation, development, and production of oil and natural gas properties in east Texas and northwest Louisiana. The company offers drilling activities and holds interests in various areas, including primarily North Minden, Beckville, Angelina River, South Henderson, Bethany Longstreet, Greenwood Waskom Metcalf, Longwood, and Caddo Pine Island. As of December 31, 2009, it had estimated proved reserves of approximately 415.3 billion cubic feet of natural gas and 0.9 million barrels of oil and condensate. It owned working interests in 466 active oil and gas wells located in 24 fields in 6 states. Goodrich Petroleum Corporation was founded in 1970 and is based in Houston, Texas.
I was tempted to write Jim Cramer and tell him that if he wanted to be associated with the Street.com and what comes out of it, he needed to look into the erroneous and incorrect articles coming out of it. While not everyone agrees, IMHO Jim is a person of integrity and sincerely wants to do right by others.
As far as GNBT responding, this is a very important time for them for it's imperative that they get the stock above $1 and keep it there for I believe 10 days due to a chance of delisting. I can't believe they'd let that happen with all the work they're doing around the globe to build this company. I really liked the idea of them going to the conference in Dubai - nothing like going where the big bucks are.:) (Course I realize Dubai is having its own problems; however, I don't think anyone would argue that there are lots of ultra-wealthy people in that area.)
GNBT doesn't take the hachet job lightly.:)
Generex Biotechnology Demands Retraction of False and Misleading Article
Company Sets Record Straight on Misinformation Spread by TheStreet.com
Companies:Generex Biotechnology Corp.
Press Release Source: Generex Biotechnology Corp. On Tuesday March 23, 2010, 8:30 am
WORCESTER, Mass., March 23, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News) (http://www.generex.com/) has demanded a retraction of and apologies for the inaccuracies in an online article published to TheStreet.com on March 19. In an entry titled "Biotech Stock Mailbag: Generex," TheStreet.com columnist Adam Feuerstein makes erroneous claims about Generex and its flagship product Generex Oral-lyn(TM), an oral insulin spray currently in Phase III clinical trials for the treatment of Type I and Type II diabetes. Generex also wishes to correct the public record by making clear the facts as outlined in the letter to TheStreet.com's counsel:
The article states, "Nifty technology, except none of the Oral-Lyn data collected by Generex has not been peer-reviewed in credible medical journals, nor has it been presented at the top-flight diabetes meetings."
FACT: A number of independent, peer-reviewed studies of Generex Oral-lyn(TM) have been published in journals including Diabetes Care. In addition, Generex Oral-lyn(TM) trial data has been presented in podium posters and abstracts at the annual meetings of the American Diabetes Association (ADA), The Endocrine Society, the European Association for the Study of Diabetes (EASD) and the International Diabetes Federation (IDF) on a regular basis over the past ten years.
The article indirectly attributes to a third-party source that he "is a skeptic because absorption of insulin through the lining of the mouth is too erratic and potentially dangerous."
FACT: Scientific data contradicts such statements, underscored by the U.S. Food & Drug Administration (FDA) stamp of approval on Generex Oral-lyn(TM) with its inclusion in the Treatment Investigational New Drug (IND) program. The absorption of insulin through the buccal mucosa is much more consistent than through subcutaneous injection, because it is absorbed directly into the blood stream. Absorption through subcutaneous injection is less consistent, as insulin collects at the injection site while it is being absorbed.
The article states, "Oral-Lyn is approved as an alternative to insulin injections in Ecuador, India, Lebanon and Algeria, claims Generex, although the company has not yet recognized revenue from the product."
FACT: Pursuing regulatory approvals overseas is an ordinary course of action for biotech and pharma companies while the U.S. FDA process in ongoing. The company will continue to pursue regulatory approvals around the globe while the Phase III study continues.
The article quotes a third-party source, "Oral insulin, respiratory insulin, buccally delivered insulin are all marketing driven technologies, they are not driven by the real need of diabetes patients."
FACT: Multiple independent studies published in Diabetes Research and Clinical Practice, Diabetic Medicine and other journals demonstrate that non-injectable insulin does address a real need of diabetes patients.
Generex Oral-lyn(TM) delivers insulin via the membranes of the oral cavity by a small device that looks like an asthma inhaler. However, unlike inhaled insulin, there is no pulmonary (lung) deposition, nor does the insulin ever enter the GI tract; it is absorbed directly into the bloodstream through the lining of the mouth. Generex Oral-lyn(TM) is in Phase III clinical trials at multiple sites in the U.S. and around the world.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been launched in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at http://www.generex.com/ or the Antigen Express website at http://www.antigenexpress.com/.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
http://finance.yahoo.com/news/Generex-Biotechnology-Demands-pz-3771542556.html?x=0&.v=1
...and this adds to the kick butt of the Street.com.:)
Generex Biotechnology Demands Retraction of False and Misleading Article
Company Sets Record Straight on Misinformation Spread by TheStreet.com
Companies:Generex Biotechnology Corp.
Press Release Source: Generex Biotechnology Corp. On Tuesday March 23, 2010, 8:30 am
WORCESTER, Mass., March 23, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News) (http://www.generex.com/) has demanded a retraction of and apologies for the inaccuracies in an online article published to TheStreet.com on March 19. In an entry titled "Biotech Stock Mailbag: Generex," TheStreet.com columnist Adam Feuerstein makes erroneous claims about Generex and its flagship product Generex Oral-lyn(TM), an oral insulin spray currently in Phase III clinical trials for the treatment of Type I and Type II diabetes. Generex also wishes to correct the public record by making clear the facts as outlined in the letter to TheStreet.com's counsel:
The article states, "Nifty technology, except none of the Oral-Lyn data collected by Generex has not been peer-reviewed in credible medical journals, nor has it been presented at the top-flight diabetes meetings."
FACT: A number of independent, peer-reviewed studies of Generex Oral-lyn(TM) have been published in journals including Diabetes Care. In addition, Generex Oral-lyn(TM) trial data has been presented in podium posters and abstracts at the annual meetings of the American Diabetes Association (ADA), The Endocrine Society, the European Association for the Study of Diabetes (EASD) and the International Diabetes Federation (IDF) on a regular basis over the past ten years.
The article indirectly attributes to a third-party source that he "is a skeptic because absorption of insulin through the lining of the mouth is too erratic and potentially dangerous."
FACT: Scientific data contradicts such statements, underscored by the U.S. Food & Drug Administration (FDA) stamp of approval on Generex Oral-lyn(TM) with its inclusion in the Treatment Investigational New Drug (IND) program. The absorption of insulin through the buccal mucosa is much more consistent than through subcutaneous injection, because it is absorbed directly into the blood stream. Absorption through subcutaneous injection is less consistent, as insulin collects at the injection site while it is being absorbed.
The article states, "Oral-Lyn is approved as an alternative to insulin injections in Ecuador, India, Lebanon and Algeria, claims Generex, although the company has not yet recognized revenue from the product."
FACT: Pursuing regulatory approvals overseas is an ordinary course of action for biotech and pharma companies while the U.S. FDA process in ongoing. The company will continue to pursue regulatory approvals around the globe while the Phase III study continues.
The article quotes a third-party source, "Oral insulin, respiratory insulin, buccally delivered insulin are all marketing driven technologies, they are not driven by the real need of diabetes patients."
FACT: Multiple independent studies published in Diabetes Research and Clinical Practice, Diabetic Medicine and other journals demonstrate that non-injectable insulin does address a real need of diabetes patients.
Generex Oral-lyn(TM) delivers insulin via the membranes of the oral cavity by a small device that looks like an asthma inhaler. However, unlike inhaled insulin, there is no pulmonary (lung) deposition, nor does the insulin ever enter the GI tract; it is absorbed directly into the bloodstream through the lining of the mouth. Generex Oral-lyn(TM) is in Phase III clinical trials at multiple sites in the U.S. and around the world.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been launched in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at http://www.generex.com/ or the Antigen Express website at http://www.antigenexpress.com/.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
http://finance.yahoo.com/news/Generex-Biotechnology-Demands-pz-3771542556.html?x=0&.v=1
So happy this guy spoke out regarding GNBT and the hatchet job by Street.com...
A problem for small retail investors looking for trusted financial news websites lies in deciphering which ones serve their interests and which ones simply offer analysis more suited for the message board forums. Often the barrier between news and bluster is blurred and one example comes to mind which I would like to highlight. Adam Feuerstein is a Senior Columnist at TheStreet.com who blogs about the pharmaceutical and biotechnology industries. I feel that Feuerstein also serves as an example of how the flow of information from "news" sources to the retail investor is distorted and broken.
Last Friday, I read first hand an example of Adam's "reporting" on a biotechnology company I follow, Generex Biotechnology (NASDAQ: GNBT). Since Generex is a micro cap company, having an article from a "news source" featuring them can result in volatile trading activity for their stock. A columnist offering a negative opinion on a company or stock can often result in a more well rounded perspective and be helpful. However, when the article presents a defamatory opinion based on untrue statements, the small retail shareholder holding shares can watch his investment deteriorate for potentially manipulative reasons.
Feuerstein takes a negative approach towards Generex in his daily featured article, titled Biotech Stock Mailbag. The problem is that he states his opinion based upon premises which I find to be blatantly false. Feuerstein belittles Generex\'s efforts in developing Oral-lyn buccal insulin spray by stating that "none of the Oral-lyn data collected by Generex has been peer-reviewed in credible medical journals, nor has it been presented at the top-flight diabetes meetings".
In the lively comment section that follows his article, I cited the numerous peer review articles which have been published by the independent researchers studying Oral-lyn in its Phase I, II and III trials, and named the plentiful "top-flight diabetes meetings" where Oral-lyn data has been presented, including having Oral-lyn data being selected for a prestigious podium presentation at last year\'s American Diabetes Association Scientific Sessions.
In reality, Generex routinely presents Oral-lyn data at all of the major diabetes events and the latest peer review article was published last month.
Feuerstein responded to my comment by stating that he gains his perspective from \"the thought leaders at the American Diabetes Association" who tell him that "Oral-Lyn is a waste of time and potentially dangerous\". Dr. Gerald Bernstein is the Vice President Medical Affairs at Generex and previously served as President of the American Diabetes Association. He presently serves on several ADA committees and is a member of the Board of Directors for the ADA\'s Research Foundation. Dr. Bernstein is a certified "thought leader at the American Diabetes Association."
Generex's Oral-lyn buccal insulin spray is in a Phase III trial in the US and has recently been conditionally approved by the FDA under a Treatment IND. The FDA website states that they will permit an investigational drug to be used under a Treatment IND if there is sufficient evidence of safety and preliminary evidence of drug efficacy. The Treatment IND approval for Oral-lyn was the first awarded by the FDA to treat diabetes. Since Feuerstein, a biotechnology reporter, is incapable of finding the numerous peer reviews detailing Oral-lyn's development, he is evidently unaware that there has never even been one single serious adverse event ever attributed to its usage. The FDA is apparently more diligent.
A reporter, analyst, or a highly regarded physician who specializes in endocrinology can certainly present a sophisticated conclusion that calls the quest to develop a non-invasive insulin drug an effort in futility.
I feel Feuerstein's tactic is to inflame, in hopes of gauging a reaction. Since Feuerstein is a Senior Columnist at TheStreet, I believe there is no excuse for offering such negligent due diligence. I find his methodology is to interact with readers in the comments section of his article by offering low wit responses. In one example, he quips that "you will find, however, that the fear of needles meme is pushed more by those seeking to market alternative to insulin injections than those who actually need to inject themselves. oral-lyn will not be proven to be safe and effective because the clinical and regulatory hurdles are simply too high".
The regulatory hurdles are high, but again I note that Generex is the first biotechnology or pharmaceutical company to engage the FDA to win conditional approval for a diabetes drug via a Treatment IND. Currently, Oral-lyn is the only non-invasive insulin available to diabetics in the US. To date, Oral-lyn has been shown to be safe and effective, and in some of the more recent Phase II studies it was concluded by the independent researchers that Oral-lyn treatment resulted in superior effect over regular injectable insulin. That factual point aside, it is also a fact that non-compliance due to various reasons for aversion to injectable insulin therapy is a serious problem resulting in a worsening condition that may lead to blindness, amputations, and transplants.
A new peer review article was published in Diabetes Care (February 2010 issue; vol 33: pp 240-245) which asked 502 people with diabetes who used insulin to complete an internet survey. More than half of those surveyed, 57 percent, said they had intentionally missed an insulin dose, and 20 percent said they regularly skipped insulin injections. Among the reasons for skipping insulin injections were complaints of injection pain, embarrassment by the need for insulin and thought that the injections interfered with their daily life. One in five stated they skip insulin injections often. Those 57 percent of diabetics that stated they sometimes skip insulin injections represent a true market of patients that may be open to a safe and effective noninvasive insulin.
The report in Diabetes Care, which is published by the American Diabetes Association, comes on the heels of The Injection Impact Report issued in 2008 by the American Association of Diabetes Educators. The report presented findings of a study which found that 33% of the surveyed patients have experienced "dread" in relation to insulin injections, 14 percent surveyed feel that insulin injections have a negative impact on their life, more than 29 percent of the surveyed feel that injecting insulin is the hardest aspect of their diabetes care. The reports published by the American Diabetes Association and the American Association of Diabetes Educators skipped Feuerstein\'s attention, which is odd since he is a professional columnist offering an opinion on the subject, and as I previously noted, he stated that he gains his perspective from "the thought leaders at the American Diabetes Association".
Feuerstein also fails to understand the true benefit of Generex's Oral-lyn buccal insulin spray. The needle-less aspect is but one of Oral-lyn's advantages over currently approved injectable insulin. The time profile for Oral-lyn is the greatest of its advantages, which enables buccal insulin dosing to mimic the first-phase insulin response seen in a healthy person. This first-phase insulin release is one of the first functions that people with diabetes lose. Dr.
Bernstein has stated that Oral-lyn is taken right before the first bite of the meal, immediately begins to be absorbed into the bloodstream through the inner lining of the mouth, peaks in 30 minutes, and works quickly allowing blood sugar levels to cleanly return to baseline within two hours.
With this very fast onset and offset of action, Oral-lyn buccal insulin spray may offer less risk of postprandial hypoglycemia as compared to conventional injected insulin therapy. With each spray of the Generex RapidMist delivery device, one unit of meal time Oral-lyn buccal insulin is rapidly delivered into the bloodstream. The amount of sprays given is determined by the amount of insulin each unique diabetic requires to cover a meal. Generex's CEO, Anna Gluskin, recently commented that they believe Oral-lyn's dose response "resembles the body's natural insulin response effectively and has the flexibility that allows patients to fine-tune their insulin treatment regimens for optimum therapeutic results."
Analogue prandial insulin is dosed approx 15 minutes before a meal, peaks in an hour, and has a duration of effect of 4 hours. Regular insulin is dosed 30 minutes before a meal, peaks in 2 hours and lingers up to 6 hours in the bloodstream. This slow acting tail activity for both analogue and regular insulin is said to often cause low blood sugar levels to occur after the glucose spike provided by the meal starts to decline. Since there is no tail of activity with Oral-lyn as there is with all other forms of injectable insulin, the risk of postprandial hypoglycemia may be greatly minimized. Hypoglycemia is a life-threatening risk, and is an important obstacle towards achieving good metabolic control. And since blood levels are back at baseline after the meal, there is no reason to gorge on post meal snacks to offset any lingering insulin, which should help avoid unhealthy weight gain.
Feuerstein has been associated with similar questionable commentary where, in my opinion, he paints an uninformed negative article about a volatile research and development biotechnology company with little regard for objective commentary.
Last year, M. E. Garza, Co-Founder of the biotech and healthcare sector news portal BioMedReports, wrote an article titled \"Wall Street Reporter's Inaccurate Reports are Becoming Patient Safety Issue Claims Biomedical Company CEO". In the article, Garza states that BioMedReports has been repeatedly contacted by officials of publicly traded companies in response to concerns that Feuerstein and TheStreet has continuously targeted small cap biomedical companies with inaccurate articles. Garza focused on the complaints from Hoji Alimi, who serves as CEO of Oculus Innovative Sciences. Feuerstein leveled an accusation that Oculus "appeared to be skirting U.S. drug laws by claiming that its wound-cleansing product containing common diluted bleach has drug-like therapeutic properties."
Garza informed that Oculus officials became concerned when they heard reports that members of the medical community and patients who use Microcyn products were adversely affected by the report. "This is becoming a patient safety issue and putting public safety at risk," Alimi told BioMedReports in an exclusive recorded interview. "It's no longer (about) attacking a company and the market potential and market cap. You're damaging public safety."
These micro and small cap biotechnology companies are in precarious positions as they attempt to navigate the toughest of regulatory environments while often searching for venues to raise the large amounts of capital needed to advance the more promising drugs in their pipeline. I feel it is easy to take a blurry and narrow focus on an area of their development to offer a distorted image of their true achievements and potential. The harder task as an investor is to take an in depth view to gain a clearer understanding of where the emerging firm may be headed in the future. When journalists present fiction as fact, under the excuse they are only presenting their personal opinion, the damages often have far reaching effect.
RJ Steffens
Disclosure: Author is Long GNBT
http://www.istockanalyst.com/article/viewarticle/articleid/3967182
So happy this guy spoke out regarding GNBT and the hatchet job by Street.com...
A problem for small retail investors looking for trusted financial news websites lies in deciphering which ones serve their interests and which ones simply offer analysis more suited for the message board forums. Often the barrier between news and bluster is blurred and one example comes to mind which I would like to highlight. Adam Feuerstein is a Senior Columnist at TheStreet.com who blogs about the pharmaceutical and biotechnology industries. I feel that Feuerstein also serves as an example of how the flow of information from "news" sources to the retail investor is distorted and broken.
Last Friday, I read first hand an example of Adam's "reporting" on a biotechnology company I follow, Generex Biotechnology (NASDAQ: GNBT). Since Generex is a micro cap company, having an article from a "news source" featuring them can result in volatile trading activity for their stock. A columnist offering a negative opinion on a company or stock can often result in a more well rounded perspective and be helpful. However, when the article presents a defamatory opinion based on untrue statements, the small retail shareholder holding shares can watch his investment deteriorate for potentially manipulative reasons.
Feuerstein takes a negative approach towards Generex in his daily featured article, titled Biotech Stock Mailbag. The problem is that he states his opinion based upon premises which I find to be blatantly false. Feuerstein belittles Generex\'s efforts in developing Oral-lyn buccal insulin spray by stating that "none of the Oral-lyn data collected by Generex has been peer-reviewed in credible medical journals, nor has it been presented at the top-flight diabetes meetings".
In the lively comment section that follows his article, I cited the numerous peer review articles which have been published by the independent researchers studying Oral-lyn in its Phase I, II and III trials, and named the plentiful "top-flight diabetes meetings" where Oral-lyn data has been presented, including having Oral-lyn data being selected for a prestigious podium presentation at last year\'s American Diabetes Association Scientific Sessions.
In reality, Generex routinely presents Oral-lyn data at all of the major diabetes events and the latest peer review article was published last month.
Feuerstein responded to my comment by stating that he gains his perspective from \"the thought leaders at the American Diabetes Association" who tell him that "Oral-Lyn is a waste of time and potentially dangerous\". Dr. Gerald Bernstein is the Vice President Medical Affairs at Generex and previously served as President of the American Diabetes Association. He presently serves on several ADA committees and is a member of the Board of Directors for the ADA\'s Research Foundation. Dr. Bernstein is a certified "thought leader at the American Diabetes Association."
Generex's Oral-lyn buccal insulin spray is in a Phase III trial in the US and has recently been conditionally approved by the FDA under a Treatment IND. The FDA website states that they will permit an investigational drug to be used under a Treatment IND if there is sufficient evidence of safety and preliminary evidence of drug efficacy. The Treatment IND approval for Oral-lyn was the first awarded by the FDA to treat diabetes. Since Feuerstein, a biotechnology reporter, is incapable of finding the numerous peer reviews detailing Oral-lyn's development, he is evidently unaware that there has never even been one single serious adverse event ever attributed to its usage. The FDA is apparently more diligent.
A reporter, analyst, or a highly regarded physician who specializes in endocrinology can certainly present a sophisticated conclusion that calls the quest to develop a non-invasive insulin drug an effort in futility.
I feel Feuerstein's tactic is to inflame, in hopes of gauging a reaction. Since Feuerstein is a Senior Columnist at TheStreet, I believe there is no excuse for offering such negligent due diligence. I find his methodology is to interact with readers in the comments section of his article by offering low wit responses. In one example, he quips that "you will find, however, that the fear of needles meme is pushed more by those seeking to market alternative to insulin injections than those who actually need to inject themselves. oral-lyn will not be proven to be safe and effective because the clinical and regulatory hurdles are simply too high".
The regulatory hurdles are high, but again I note that Generex is the first biotechnology or pharmaceutical company to engage the FDA to win conditional approval for a diabetes drug via a Treatment IND. Currently, Oral-lyn is the only non-invasive insulin available to diabetics in the US. To date, Oral-lyn has been shown to be safe and effective, and in some of the more recent Phase II studies it was concluded by the independent researchers that Oral-lyn treatment resulted in superior effect over regular injectable insulin. That factual point aside, it is also a fact that non-compliance due to various reasons for aversion to injectable insulin therapy is a serious problem resulting in a worsening condition that may lead to blindness, amputations, and transplants.
A new peer review article was published in Diabetes Care (February 2010 issue; vol 33: pp 240-245) which asked 502 people with diabetes who used insulin to complete an internet survey. More than half of those surveyed, 57 percent, said they had intentionally missed an insulin dose, and 20 percent said they regularly skipped insulin injections. Among the reasons for skipping insulin injections were complaints of injection pain, embarrassment by the need for insulin and thought that the injections interfered with their daily life. One in five stated they skip insulin injections often. Those 57 percent of diabetics that stated they sometimes skip insulin injections represent a true market of patients that may be open to a safe and effective noninvasive insulin.
The report in Diabetes Care, which is published by the American Diabetes Association, comes on the heels of The Injection Impact Report issued in 2008 by the American Association of Diabetes Educators. The report presented findings of a study which found that 33% of the surveyed patients have experienced "dread" in relation to insulin injections, 14 percent surveyed feel that insulin injections have a negative impact on their life, more than 29 percent of the surveyed feel that injecting insulin is the hardest aspect of their diabetes care. The reports published by the American Diabetes Association and the American Association of Diabetes Educators skipped Feuerstein\'s attention, which is odd since he is a professional columnist offering an opinion on the subject, and as I previously noted, he stated that he gains his perspective from "the thought leaders at the American Diabetes Association".
Feuerstein also fails to understand the true benefit of Generex's Oral-lyn buccal insulin spray. The needle-less aspect is but one of Oral-lyn's advantages over currently approved injectable insulin. The time profile for Oral-lyn is the greatest of its advantages, which enables buccal insulin dosing to mimic the first-phase insulin response seen in a healthy person. This first-phase insulin release is one of the first functions that people with diabetes lose. Dr.
Bernstein has stated that Oral-lyn is taken right before the first bite of the meal, immediately begins to be absorbed into the bloodstream through the inner lining of the mouth, peaks in 30 minutes, and works quickly allowing blood sugar levels to cleanly return to baseline within two hours.
With this very fast onset and offset of action, Oral-lyn buccal insulin spray may offer less risk of postprandial hypoglycemia as compared to conventional injected insulin therapy. With each spray of the Generex RapidMist delivery device, one unit of meal time Oral-lyn buccal insulin is rapidly delivered into the bloodstream. The amount of sprays given is determined by the amount of insulin each unique diabetic requires to cover a meal. Generex's CEO, Anna Gluskin, recently commented that they believe Oral-lyn's dose response "resembles the body's natural insulin response effectively and has the flexibility that allows patients to fine-tune their insulin treatment regimens for optimum therapeutic results."
Analogue prandial insulin is dosed approx 15 minutes before a meal, peaks in an hour, and has a duration of effect of 4 hours. Regular insulin is dosed 30 minutes before a meal, peaks in 2 hours and lingers up to 6 hours in the bloodstream. This slow acting tail activity for both analogue and regular insulin is said to often cause low blood sugar levels to occur after the glucose spike provided by the meal starts to decline. Since there is no tail of activity with Oral-lyn as there is with all other forms of injectable insulin, the risk of postprandial hypoglycemia may be greatly minimized. Hypoglycemia is a life-threatening risk, and is an important obstacle towards achieving good metabolic control. And since blood levels are back at baseline after the meal, there is no reason to gorge on post meal snacks to offset any lingering insulin, which should help avoid unhealthy weight gain.
Feuerstein has been associated with similar questionable commentary where, in my opinion, he paints an uninformed negative article about a volatile research and development biotechnology company with little regard for objective commentary.
Last year, M. E. Garza, Co-Founder of the biotech and healthcare sector news portal BioMedReports, wrote an article titled \"Wall Street Reporter's Inaccurate Reports are Becoming Patient Safety Issue Claims Biomedical Company CEO". In the article, Garza states that BioMedReports has been repeatedly contacted by officials of publicly traded companies in response to concerns that Feuerstein and TheStreet has continuously targeted small cap biomedical companies with inaccurate articles. Garza focused on the complaints from Hoji Alimi, who serves as CEO of Oculus Innovative Sciences. Feuerstein leveled an accusation that Oculus "appeared to be skirting U.S. drug laws by claiming that its wound-cleansing product containing common diluted bleach has drug-like therapeutic properties."
Garza informed that Oculus officials became concerned when they heard reports that members of the medical community and patients who use Microcyn products were adversely affected by the report. "This is becoming a patient safety issue and putting public safety at risk," Alimi told BioMedReports in an exclusive recorded interview. "It's no longer (about) attacking a company and the market potential and market cap. You're damaging public safety."
These micro and small cap biotechnology companies are in precarious positions as they attempt to navigate the toughest of regulatory environments while often searching for venues to raise the large amounts of capital needed to advance the more promising drugs in their pipeline. I feel it is easy to take a blurry and narrow focus on an area of their development to offer a distorted image of their true achievements and potential. The harder task as an investor is to take an in depth view to gain a clearer understanding of where the emerging firm may be headed in the future. When journalists present fiction as fact, under the excuse they are only presenting their personal opinion, the damages often have far reaching effect.
RJ Steffens
Disclosure: Author is Long GNBT
http://www.istockanalyst.com/article/viewarticle/articleid/3967182
I can't speak for anyone else; however, I can tell you I'm not selling. Instead if I have money I will average in, but we each have to do what is right for us.
Smart thing to do. There are many opportunities to trade this; however, I usually hold onto most of my shares for I keep thinking I'll sell then it'll ramp.:) Looking at the chart when it moved to $5 you can see how it ran and there's even more reason for the company to move big now.
GNBT...Thank you. I was tempted to write him and give him my thoughts as to his article; however, I thought it would be useless. Another author of something from the Street.com had written something totally wrong and I wrote him and even posted it on the GNBT BB. He was very nice, but in short basically said he assumed things since he covers so many stocks under $5. He never retracted his story. Then I thought I'd write to www.marketplace.com or another credible site and ask them if they'd consider a guest writer. I knew it would take many hours to write something good for I'd research it, but decided agsinst it for I'm teaching five classes a week and have lots of writing to grade. In short, my cup is full. Our GNBT will shine when it's ready and any of these drops I'm trying to perceive of being opportunities to add.
Lexi
Regarding GNBT, I made several posts on their BB about the article last week by the Street.com and what I thought of it. I'm still long and strong.:)
GNBT...Don't know how much further they'll drop it, but if it does go to .45 and makes a double bottom, IMHO that would be a place to load the boat. I've bought all over the place and have a significant amount of shares with an average of around .62 or .63. BTW, someone on SI was telling me she had HGSI and a negative article came out just before it took off like a rocket and unfortunately she sold due to it. Just another example of the need to "shut out the noise" and do what you know is right by your own DD.
The reasoning in the article is faulty in many ways IMHO. He talks about the oral insulin not being effective for someone who has a sore in his mouth. I can see where that can be true; however, how many people on insulin have a sore in their mouth as compared to the whole group? In addition, while I'm not a diabetic or overly knowledgeable about it other than reading the basics; it seems to me that if you do have a sore in your mouth and there is the concern that the dose won't be accurate, why couldn't you go on the shots for that period of time? As a person who saw what agony my husband went through with all the blood tests he had to have frequently and being stuck with needles, I'd think the oral dose would be a real plus to someone on insulin rather than having to use a needle.
He's quick to mention someone in the medical community who is negative on GNBT, yet he ignores Dr Gerald Bernstein, VP Medical Affairs Generex, former President of American Diabetes Association
who says this:
"It’s extremely safe by all the studies that have been done so far, including two years in animal tests. We haven’t seen allergic reaction. The lining of the mouth hasn’t shown any abnormalities. The buccal mucosa is an extra-tough and resilient tissue, it’s beaten up all the time. People bite themselves or burn themselves. Whatever doesn’t get absorbed is going to go to the stomach. Now the insulin molecule is unprotected and therefore it will be denatured by the acid and then broken down. There are no side effects."
You can ALWAYS find someone to make your point as the Street.com did and of course I did just now in my post. The difference is that in my posts here, I've recognized that there are many facets to the potential of GNBT and the other author did not.
Lexi
Fib retracements for GNBT using the low of .08 and the high of 1.14.
38% = .735
50% = .61
62% = .48
79% = .31
BTW, significant buying at EOD was a good sign. Candle with long tail shows buyers were in charge.
This is part of a post I made on a BB at SI regarding GNBT...
One thing I teach my students is to do research and I tried to apply the same principles to that article on GNBT today. First of all, does the guy really even know what he's talking about? With the brief study of his biography, this really isn't even his field.
============
Adam Feuerstein
TheStreet.com Senior ColumnistRealMoney
RSS Feed Email This Author
Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
====================
His focus is on the oral insulin and there is much more to GNBT than that. He totally disregards the income potential of CVS selling GNBT's diet aide. He seems to think we should take his opinion that, "Generex is a total bust." Do you really think the co-founder of AMGN would endanger his life's reputation with the reports that he put out on GNBT a few months ago stating the direction of the company? I think he has much more credibility than Adam with his political science degree.
Next, it looks like most of the articles Adam writes are negative about these stocks we trade. My first thought was I wonder if his friends and relatives are benefiting from these calls he makes trashing stocks. In addition, the person who taught me to trade kept telling me, "Shut out the noise." He meant to do my own DD and read the chart while not listening to everyone else. In short, I still believe in the company and while Adam might have affected the stock in the short-term, it'll do fine as the good news continues IMHO.
Lexi
GNBT...Getting a real hatchet job from Street.com. However, what's new? It's not uncommon for them. Author of article seems to be negative on many stocks he writes about.
http://www.thestreet.com/story/10706508/1/biotech-stock-mailbag-generex.html
CPST...Thanks. One I've traded lots in the past.
GNBT...Be still my heart...:) It keeps making new HODs(rare)...and a block of 100,000 shares just went through. Volume very high for so early in the day.
HDY..Nice move up. Congrats.
GNBT...LOL So true. Announcement today basically shows they continue to work to make their company a success.
Generex Establishes Relationships For Development Of Distribution Network For Generex Oral-Lyn(R) Under FDA's Expanded Access Treatment IND ProgramLast update: 3/4/2010 9:32:30 AM(MORE TO FOLLOW) Dow Jones Newswires (212-416-2400)March 04, 2010 09:32 ET (14:32 GMT)
Generex Establishes Relationships For Development Of Distribution Network For Generex Oral-Lyn(R) Under FDA's Expanded Access Treatment IND ProgramLast update: 3/4/2010 9:32:30 AM(MORE TO FOLLOW) Dow Jones Newswires (212-416-2400)March 04, 2010 09:32 ET (14:32 GMT)
GNBT...Was reading this March 3rd report on the company and found this:
The Company has 180 calendar days, or until May 5, 2010, to regain compliance... Wasn't sure when the date was before reading this info.
http://www.itsallbull.net/reports/NASDAQCM_GNBT_DETAILED.pdf
GNBT...Just saw a commercial from CVS regarding GNBT's diet product. In closing, they said it is just one of GNBT's products they sell. Thought that was a real positive.:)
GNBT...Just saw a commercial from CVS regarding GNBT's diet product. In closing, they said it is just one of GNBT's products they sell. Thought that was a real positive.:)
Right...
GNBT...Could this be it?
Our common stock is listed on the NASDAQ Capital Market under the symbol "GNBT." The last sale price of our common stock on January 28, 2010, as reported by NASDAQ, was $0.59 per share. ***None of the other securities offered under this prospectus are publicly traded.***
So could it already be over?
GNBT...Thanks. I was looking too and couldn't find it.